A Metabolomic Analysis of Omega-3 Fatty Acid-Mediated Attenuation of Western Diet-Induced Nonalcoholic Steatohepatitis in LDLR⁻/⁻ Mice

Christopher M. Depner¹,³, Maret G. Traber¹,³, Gerd Bobe²,³, Elizabeth Kensicki⁴, Kurt M. Bohren⁵, Ginger Milne⁶, Donald B. Jump¹,³*

¹ The Nutrition Program, School of Biological and Population Health Sciences, Oregon State University, Corvallis, Oregon, United States of America, ² Department of Animal and Rangeland Sciences, Oregon State University, Corvallis, Oregon, United States of America, ³ Linus Pauling Institute, Oregon State University, Corvallis, Oregon, United States of America, ⁴ Metabolon, Inc., Durham, North Carolina, United States of America, ⁵ United States Department of Agriculture, Agricultural Research Service, Children’s Nutrition Research Center, Baylor College of Medicine, Houston, Texas, United States of America, ⁶ Eicosanoid Core Laboratory, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America

Abstract

Background: Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease and a risk factor for cirrhosis, hepatocellular carcinoma and liver failure. Previously, we reported that dietary docosahexaenoic acid (DHA, 22:6,n-3) was more effective than eicosapentaenoic acid (EPA, 20:5,n-3) at reversing western diet (WD) induced NASH in LDLR⁻/⁻ mice.

Methods: Using livers from our previous study, we carried out a global non-targeted metabolomic approach to quantify diet-induced changes in hepatic metabolism.

Results: Livers from WD + olive oil (WD + O)-fed mice displayed histological and gene expression features consistent with NASH. The metabolomic analysis of 320 metabolites established that the WD and n-3 polyunsaturated fatty acid (PUFA) supplementation had broad effects on all major metabolic pathways. Livers from WD + O-fed mice were enriched in saturated (SFA) and monounsaturated fatty acids (MUFA), palmitoyl-sphingomyelin, cholesterol, n-6 PUFA, n-6 PUFA-containing phosphoglycerolipids, n-6 PUFA-derived oxidized lipids (12-HETE) and depleted of C₂₀₋₂₂ n-3 PUFA-containing phosphoglycerolipids, C₂₀₋₂₂ n-3 PUFA-derived oxidized lipids (18-HEPE, 17,18-DIHETE) and S-lactoylglutathione, a methylglyoxal detoxification product. WD + DHA was more effective than WD + EPA at attenuating WD + O-induced changes in NASH gene expression markers, n-6 PUFA and oxidized lipids, citrate and S-lactosyl glutathione. Diet-induced changes in hepatic MUFA and sphingolipid content were associated with changes in expression of enzymes involved in MUFA and sphingolipid synthesis. Changes in hepatic oxidized fatty acids and S-lactoylglutathione, however, correlated with hepatic n-3 and n-6 C₂₀₋₂₂ PUFA content. Hepatic C₂₀₋₂₂ n-3 PUFA content was inversely associated with hepatic α-tocopherol and ascorbate content and positively associated with urinary F2- and F3-isoprostanes, revealing diet effects on whole body oxidative stress.

Conclusion: DHA regulation of hepatic SFA, MUFA, PUFA, sphingomyelin, PUFA-derived oxidized lipids and S-lactoylglutathione may explain the protective effects of DHA against WD-induced NASH in LDLR⁻/⁻ mice.

Citation: Depner CM, Traber MG, Bobe G, Kensicki E, Bohren KM, et al. (2013) A Metabolomic Analysis of Omega-3 Fatty Acid-Mediated Attenuation of Western Diet-Induced Nonalcoholic Steatohepatitis in LDLR⁻/⁻ Mice. PLoS ONE 8(12): e83756. doi:10.1371/journal.pone.0083756

Editor: Michael Müller, Wageningen University, Netherlands

Received August 27, 2013; Accepted November 7, 2013; Published December 17, 2013

Copyright: © 2013 Depner et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by grants from the United States Department of Agriculture National Institute of Food and Agriculture (2009-65200-05846) and the National Institutes of Health Grants to DBJ (DK043220; DK094600). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: As employees of Metabolon, Inc., EK and KMB have or have had affiliations with or financial involvement with Metabolon, Inc. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

* E-mail: Donald.Jump@oregonstate.edu

Introduction

Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is defined as hepatic steatosis with inflammation and hepatic injury [1]. Once developed, NASH can progress to hepatic fibrosis, cirrhosis, hepatocellular carcinoma and end stage liver disease [2]. Approximately 30% to 40% of individuals with hepatic steatosis...
progress to NASH [2]; and the prevalence of NASH in the general population ranges from 3% to 5% [3]. Given its association with obesity, type 2 diabetes (T2D) and metabolic syndrome (MetS); and its increasing prevalence and clinical severity, NASH is quickly becoming a significant public health concern. NASH is estimated to be the leading cause of liver transplantation in the United States by 2020 [4].

The development of NASH has been proposed to follow a two-hit mechanism [5]. The “1st Hit” involves excess lipid accumulation in the liver, which sensitizes the liver to the “2nd Hit”. The “2nd Hit” involves inflammation, oxidative stress, liver damage and fibrosis. While the two-hit hypothesis is helpful in understanding processes that contribute to development and progression of NASH, our overall understanding of NASH is incomplete and thus has limited the development of therapies specifically targeted to NAFLD/NASH. The standard of care for patients diagnosed with NAFLD or NASH is to treat for liver disease and the associated co-morbidities including obesity, T2D, hyperlipidemia, and MetS [1,6,7]. As such, a more complete understanding of NASH is needed to address this imminent public health burden.

We recently reported that the capacity of dietary docosahexaenoic acid (DHA; 22:6,n-3) to suppress markers of hepatic damage (plasma alanine [ALT] and aspartate [AST] amino-transferases), hepatic inflammation (C-type lectin domain family 4-F [Clec4F], F4/80, toll-like receptor 4 [TLR4]), oxidative stress (NADPH oxidase subunits NOX2, p22phox, p40phox, p47phox, and p67phox), and fibrosis (pro-collagen 1A1 [procoll1A1], transforming growth-factor β1 [TGF β1]) was greater than dietary eicosapentaenoic acid (EPA, 20:5,n-3) to suppress markers of hepatic damage (plasma alanine [ALT] and aspartate [AST] amino-transferases), hepatic inflammation (C-type lectin domain family 4-F [Clec4F], F4/80, toll-like receptor 4 [TLR4]), oxidative stress (NADPH oxidase subunits NOX2, p22phox, p40phox, p47phox, and p67phox), and fibrosis (pro-collagen 1A1 [procoll1A1], transforming growth-factor β1 [TGF β1]) was greater than dietary eicosapentaenoic acid (EPA, 20:5,n-3) using the LDLR-/- mouse model of western diet (WD) induced NASH [8]. While dietary DHA provided significant benefit in preventing NASH progression, neither EPA nor DHA fully attenuated WD-induced hepatosteatosis. The outcome of this study established that a major target of DHA in the liver is the control of inflammation, oxidative stress, and fibrosis, the key features that distinguish NASH from benign steatosis.

To advance our understanding of both the progression of NASH and the impact from EPA and DHA supplementation on NASH, we conducted a non-targeted global metabolomics analysis of livers from our previous study [8]. LDLR-/- mice were fed the WD for 16 weeks with and without EPA and/or DHA supplementation. A major advantage of this study was that it provided an analysis of perturbed hepatic metabolism associated with advanced diet-induced NASH, the most clinically detrimental stage of NAFLD. Multiple studies have previously employed lipidomic and proteomic strategies to identify new NAFLD/NASH biomarkers [9-12]. Only a few studies have used metabolomics specifically on liver to assess changes associated with NAFLD or NASH [13-15]. As far as we are aware, this is the first study to use metabolomics to identify pathways involved in diet-induced NASH and also to evaluate the impact of dietary EPA and DHA on NASH-induced changes in hepatic metabolism. Our overall goal was to identify pathways contributing to NASH and assess the impact of EPA and DHA on the regulation of those pathways. Accordingly, we identified several metabolic targets of WD and C20:2 ω-3 PUFA that potentially contribute to the development of NASH including sphingo- and phospho-glycerol lipid metabolism, membrane remodeling, oxidized lipid formation and methylglyoxal (MG) detoxification. MG is a metabolite involved advanced glycation end product formation and has been linked to NAFLD [16].

Materials and Methods

Animals and diets

All procedures for the use and care of animals for laboratory research were approved by the Institutional Animal Care and Use Committee at Oregon State University. Male LDLR-/- mice [C57BL/6J background, Jackson Laboratories] at 2 months of age were fed one of the following five diets *ad libitum* for 16 weeks; each group consisted of 8 male mice. The control diet was Purina chow 5001 consisting of 13.5% energy as fat and 58.0% energy as carbohydrates. The western diet (WD) [D12709B, Research Diets] was used to induce NAFLD/NASH; it consists of 17% energy as protein, 43% energy as carbohydrate and 41% energy as fat; cholesterol was at 0.2% w/w. The WD was supplemented with olive oil (WD + O), EPA (WD + E), DHA (WD + D) or EPA plus DHA (WD + E + D). Supplementation of the WD with olive oil, EPA, DHA or EPA + DHA increased total fat energy to 44.7% and reduced protein and carbohydrate energy to 15.8 and 39.5%, respectively. Olive oil was added to the WD to ensure a uniform level of energy from fat, protein and carbohydrate in all WD diets. Preliminary studies established that the addition of olive oil to the WD had no effect on diet-induced fatty liver disease in LDLR-/- mice. The C20:2 ω-3 PUFA in the WD + E, WD + D and WD + E + D diets was at 2% total energy. A detailed analysis and description of the diets was reported previously [8]. At the end of the 16 week feeding period, all mice were fasted overnight (18:00 to 08:00 the next day) then euthanized (isoflurane anesthesia and exsanguination) at 08:00 for the collection of blood and liver [17].

Urinary F2- and F3-isoprostanes (F2- & F3-Isop)

After 15 weeks of feeding, 2 pairs of 3 mice from each diet group were placed in metabolic cages for 24 hour urine collections. Urine was stored at -80°C until analyzed for F2- and F3-isoprostanes. Results were normalized to urinary creatinine as previously described [17-19].

RNA extraction and qRT-PCR

Total RNA was extracted from liver and specific transcripts were quantified by qRT-PCR [8,20]. Primers for each transcript are listed in Table S1. Cyclophilin was used as the internal control for all transcripts.

Lipid extraction and analysis

Hepatic total lipid extracts were prepared as previously described [8,20]. Hepatic polar and neutral lipids were separated from the total lipid extracts by solid phase extraction using established methods [21,22]. Briefly, an Alltech aminopropyl disposable cartridge column was equilibrated with 2 column volumes of hexane. Total lipid extract in chloroform
was loaded onto the column and washed with chloroform. Neutral lipids were eluted with chloroform-2-propanol (2:1). Non-esterified fatty acids (NEFA) were eluted with diethyl ether-2%acetic acid. Lastly, glycerophospholipids were eluted with methanol. Thin-layer chromatography was used to confirm separation of lipid classes (Figure S1)[8]. Fatty acid methyl esters were prepared from the polar, NEFA and neutral lipids and quantified by gas chromatography [8,20].

**Plasma Endotoxin**

Plasma endotoxin was assayed using the Limulus Amebocyte lysate assay procedure according to the manufacturer’s instructions (Charles River).

**Metabolomic analysis**

The non-targeted global metabolomic analysis was carried out by Metabolon, Inc. (Durham, NC). Briefly, the sample preparation process was carried out using the automated MicroLab STAR® system from Hamilton Company. Recovery standards were added prior to the first step in the extraction process for quality control purposes. Sample preparation was conducted using a proprietary series of organic and aqueous extractions to remove the protein fraction while allowing maximum recovery of small molecules. The resulting extract was divided into two fractions; one for analysis by liquid chromatography (LC) and one for analysis by gas chromatography (GC). Samples were placed briefly on a TurboVap® (Zymark) to remove the organic solvent. Each sample was then frozen and dried under vacuum. Samples then prepared for the appropriate instrument, either LC/MS or GC/MS.

The LC/mass spectrometer (MS) portion of the platform was based on a Waters ACQUITY UPLC and a Thermo-Finnigan LTQ mass spectrometer, which consisted of an electrospray ionization (ESI) source and linear ion-trap (LIT) mass analyzer. The GC column was 5% phenyl and the temperature ramp was from 40° to 300° C in a 16 minute period. Samples were analyzed on a Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole mass spectrometer using electron impact ionization. Identification of known chemical entities was based on comparison to library entries of authentic standards. A detailed description of this platform has been published previously [13]. The metabolomic data is included as Supplementary Information (File S1).

MultiExperiment Viewer (http://www.tm4.org) was used to analyze and represent the metabolomic data as a heat map. Detailed bioinformatic analysis was carried out using MetaboAnalyst (http://www.metaboanalyst.ca). The original metabolomics data was generated from analysis of mass equivalent-samples. However, to account for differential cellular protein content arising from the massive accumulation of lipid in livers, the original data was normalized to protein abundance/sample. In addition, gene expression data (delta C, values) from our previous study [8] was added to the metabolomics data file. These transcripts serve as markers for NASH and lipid metabolism and include: monocyte chemoattractant protein-1 (MCP1), cluster of differentiation 68 (CD68), NADPH-oxidase-2 (NOX2), toll-like receptor-4 (TLR4), procollagen1A1 (proCOL1A1), and stearoyl CoA desaturase-1 (SCD1). This analysis allowed us to visualize how metabolites and NASH gene expression markers (transcripts) changed with treatment. The metabolomic analysis (MetaboAnalyst (http://www.metaboanalyst.ca) included several statistical analyses, i.e., principal component analysis (Figure S2), volcano plots, partial least squares-discriminant analysis, significance analysis of microarray, empirical Bayesian analysis of microarray, hierarchical clustering, random forest.

**Statistical analysis**

Changes in metabolites, proteins (immunoblot), endotoxin, and gene transcripts were analyzed by one-way ANOVA to detect significant differences between groups. Data were analyzed for homogenous variances by the Levine test. If unequal variances were detected, data were log-transformed. ANOVA analysis was performed on both transformed and untransformed data. A p-value < 0.05 was considered significantly different. Values are reported as mean ± SD.

**Results**

**Overview of diet effects on hepatic metabolites**

LDLR<sup>-/-</sup> mice fed the WD + O for 16 weeks developed a robust NASH phenotype characterized by hepatosteatosis, hepatic damage (plasma ALT & AST), inflammation (MCP1), oxidative stress (Hmox-1 and NOX2) and fibrosis (ProCol1A1). While including C<sub>20:2</sub> n-3 PUFA at 2% total energy in the WD did not fully prevent hepatosteatosis, NASH markers of hepatic damage, inflammation, oxidative stress, and fibrosis, were significantly attenuated. The WD + D diet was more effective than the WD + E diet at reversing WD + O induced NASH markers [8].

To gain additional insight into how the WD + O and dietary C<sub>20:2</sub> n-3 PUFA affected hepatic metabolism, we carried out a non-targeted global metabolomic analysis using livers from our previous study [8]. The analysis identified 524 total metabolites; 320 known and 204 unknown metabolites. When examined by principal component analysis, the 320 known metabolites in mice fed the Chow diet had considerable variation in composition, while metabolites in the WD + D group differed from the other WD diets. Also, the WD + O differed from WD + E and WD + E + D in the second principal component (Figure S2).

A heat map of the 320 known metabolites is presented as fold-change relative to Chow-fed (control) mice (Figure 1). The known metabolites were associated with 8 major pathways including amino acid, carbohydrate, energy, lipid, nucleotide, peptide, vitamins and cofactors, and xenobiotics; xenobiotics (8 metabolites) were excluded from further analysis. The analysis revealed that metabolites associated with lipid and amino acid pathways were most affected by diet (Figure 2A). Over 50% of the metabolites in each pathway were significantly affected by the dietary treatments. When compared to Chow-fed mice, the WD + O diet affected all pathways; suppression of metabolite abundance was more common in the amino acid, carbohydrate, energy, nucleotide, and vitamin & cofactor pathways (Figure 2B). Dietary supplementation with EPA and
or DHA attenuated many of the WD + O-induced effects (Figure 2C). Clearly the WD, without and with EPA or DHA supplementation has broad effects on liver metabolism affecting all major pathways.

Since feeding mice the WD + D was better than WD + E at reversing WD + O effects on the liver [8], we prepared a volcano plot comparing chow-fed versus WD + O-fed mice and WD + O-fed versus WD + D-fed mice (Figure 3). Volcano plots allow for the visualization of the distribution of p-values versus fold-change for all known metabolites and selected RNA transcripts [Tables S2 - S3 for the full volcano plot data]. Feeding mice the WD + O for 16 weeks led to an accumulation of palmitoyl-sphingomyelin, MUFA (18:1,n-9 and 18:1,n-7), n-6 PUFA (20:4, n-6) as well as vitamins or their metabolites, including α-tocopherol (vitamin E) and 5-methyltetrahydrofolate (5MeTHF) (Figure 3A). Feeding mice the WD + O diet also lowered hepatic n-3 PUFA (EPA, DHA) and oxidized lipids derived from n-3 PUFA (18-hydroxyeicosapentaenoic acid [18-HEPE] and 17,18-dihydroxyeicosatetraenoic acid [17,18-DiHETE]). Diet-induced changes in hepatic MUFA, n-3 and n-6 PUFA content paralleled changes reported previously using gas chromatographic analysis of total hepatic fatty acid content [8]. Ingestion of the WD + O diet was also associated with the loss of S-lactoylglutathione, a detoxification product of methylglyoxal (MG); MG is involved in forming advanced glycation end products (AGEP) [23] and promotes NASH [16]. These changes in hepatic metabolites were associated with hepatic damage (ALT and AST) and the induction of multiple gene expression markers of NASH, including MUFA synthesis (SCD1), inflammation (MCP1, CD68, TLR4), oxidative stress (HMOX-1 & NOX2) and fibrosis (proCOL1A1).

The comparison of WD + O versus WD + D (Figure 3B) shows that many of the metabolites that changed in response to the WD + O diet (Figure 3A) were reversed (partially or totally) by the WD + D. For example, hepatic C20:22 n-3 PUFA and their oxidized lipid metabolites increased, as did S-lactoylglutathione. Hepatic MUFA, n-6 PUFA, n-6 PUFA-derived oxidized lipids, palmitoyl-sphingomyelin and α-tocopherol, in contrast, were decreased in livers of WD + D-fed mice. Changes in hepatic content of these metabolites are
associated with a corresponding decline in the NASH gene expression markers, i.e., MCP1, CD68, ProCOL1A1, NOX2, SCD1 and TLR4.

**Plasma endotoxin and hepatic palmitoyl-sphingomyelin**

Monocyte chemo-attractant protein-1 (MCP1) represents an early and robust marker of inflammation; MCP1 mRNA was induced >30-fold by feeding LDLR<sup>-/-</sup> mice the WD + O [8]. There are several sources of inflammatory signals that impact the liver including oxidized LDL (ox-LDL) [24], endotoxin [25,26] and products from hepatocellular death resulting from hepatic injury [27,28]. In this report, we focused on endotoxin, which originates from the gut either by increased gut permeability or co-transport with chylomicron [26,29,30]. Plasma endotoxin of mice fed the WD + O is ~15-fold (p<0.05) higher than mice fed chow (Figure 4). Plasma endotoxin is well-induced in all groups fed the WD, regardless of the absence or presence of dietary C<sub>20-22</sub>n-3 PUFA.

CD14 is the cellular receptor for endotoxin and it is linked to toll-like receptor-4 (TLR4) function [31]. Activation of TLR4 regulates a pathway that results in the accumulation of NFκB (p50 & p65 subunits) in the nucleus. MCP1 is one of many gene targets of NFκB [8]. TLR4 functions within lipid rafts, membrane microdomains enriched in sphingomyelin, cholesterol and phospholipids with saturated acyl chains [31]. Changes in hepatic palmitoyl-sphingomyelin correlated well with hepatic MCP1 expression, hepatic total MUFA, palmitate (16:0) and hepatic damage (plasma AST) (Figure 5 A-D). DHA- and EPA-containing diets appear equally effective at reversing WD + O-induced changes in hepatic palmitoyl-sphingomyelin, MUFA, SFA and plasma AST.

Hepatic content of palmitoyl-sphingomyelin and metabolites involved in sphingomyelin synthesis (sphinagine) and ceramide degradation (sphingosine) were elevated in mice fed the WD + O diet (Figure 6 A-C) suggesting effects on both synthesis of sphingomyelin and ceramide degradation. We examined the expression of enzymes involved in sphingomyelin synthesis, including serine-palmitoyl transferase long chain base subunit-1 & 2 (SPTLC1 & 2) and phosphatidylcholine:ceramide choline phosphotransferase 1 & 2 (SGMS1 & 2) (Figure 6C). Of these, hepatic mRNA levels of SPTLC1, SPTLC2 and SGMS1 were induced by WD + O. WD +D, but not WD + E, blocked the WD + O induction of SPTLC1 and SGMS1, but not SPTLC2. While the involvement of sphingolipid synthesis in the progression NAFLD has been documented [32], this analysis suggests DHA modifies hepatic sphingolipid levels, at least in part, by controlling sphingolipid synthesis. We suggest these changes in hepatic sphingomyelin alter membrane lipid composition and TLR4 signaling.

**One-carbon metabolism**

A key component of sphingomyelin is choline, an essential nutrient (Figure 7A & B). Quantitation of metabolites involved in choline metabolism showed that the WD + O diet increased formation of phosphoethanolamine, choline, choline phosphate, 5MeTHF, dimethylglycine, cysteine, and cytidine 5’-diphosphocholine (CDP-choline). EPA and/or DHA containing diets attenuated the WD + O-induced changes in

---

**Figure 4. Diet effects on plasma endotoxin.** Plasma endotoxin was quantified as described in Materials and Methods. Results are presented as Plasma Endotoxin, Fold Change. Mean ± SD relative to chow fed mice; *, P ≤ 0.05 versus chow. doi: 10.1371/journal.pone.0083756.g004

**Figure 5. Diet effects on hepatic markers of inflammation, SFA, MUFA and damage.** Linear regression analysis of hepatic palmitoyl-sphingomyelin (Fold Change relative to chow) versus hepatic MCP1 mRNA expression (fold change relative to chow) (Panel A); hepatic total MUFA content (μmoles total MUFA/mg protein) (Panel B); hepatic palmitate (16:0) (μmoles /mg protein) (Panel C); and plasma AST (units (U)/ml of plasma) (Panel D). Palmitoyl-sphingomyelin was quantified in the metabolomic analysis while hepatic MCP1, MUFA, palmitate, and plasma AST were quantified and reported previously [8]. Each data point in Panels A-D represents the relative abundance of palmitoyl-sphingomyelin and hepatic MCP1 mRNA, MUFA, 16:0 or plasma AST for each animal. The groups are colored-coded to facilitate visualization of the distribution in each group.

doi: 10.1371/journal.pone.0083756.g005
phosphoethanolamine, choline phosphate, and 5MeTHF. One explanation is that increased choline used for sphingomyelin synthesis in WD + O fed mice was prevented by decreased sphingomyelin synthesis in WD + D-fed mice.

Also quantified in this analysis are the oxidative stress markers associated with this pathway; including reduced (GSH) and oxidized (GSSH) glutathione and methionine sulfoxide. Of these metabolites, only methionine sulfoxide was significantly elevated in livers of mice fed WD + E and WD + D. These results suggest that EPA and DHA have selective effects on hepatic oxidative stress, affecting hepatic levels of methionine sulfoxide, but not GSH or GSSH.

Saturated (SFA) and monounsaturated fatty acids (MUFA)

Hepatic SFA and MUFA content correlates with increased palmitoyl-sphingomyelin (Figure 5). The WD contains high levels of SFA and MUFA and feeding LDLR⁻/⁻ mice the WD + O diet leads to ~6-fold accumulation of 16:0 and >10-fold accumulation of 18:1,n-9 and 18:1,n-7 in the liver [8]. The WD + O diet also induced enzymes involved in MUFA synthesis, including SCD1 as well as two fatty acid elongases, ELOVL5 and ELOVL6 [8], suggesting that the massive accumulation of MUFA was due to both diet and de novo SFA and MUFA synthesis. The metabolomic analysis indicated that hepatic citrate was elevated in livers of WD + O fed mice versus livers of chow fed mice (Figure 8). Increased levels of citrate inhibit phosphofructokinase-1, and therefore glucose-6 phosphate levels trend higher in WD + O fed mice. Increased hepatic citrate also supports increased de novo lipogenesis (DNL) which leads to the accumulation of 16:0, 18:1,n-9, and 18:1,n-7. DHA-containing diets significantly lowered hepatic citrate when compare to WD + O fed mice.

SCD1 is a key enzyme involved in hepatic MUFA synthesis and its expression is regulated by multiple transcription factors, including sterol regulatory element binding protein (SREBP1), carbohydrate response element binding protein (ChREBP), liver X receptor (LXR), and peroxisome proliferator activated receptor γ2 (PPARγ2) [33]. Furthermore, regulation of SCD1 has been linked to SPTLC activity and has been implicated in sphingomyelin synthesis [34]. We previously reported the effects of a high-fat high-cholesterol diet and addition of C₂₀₋₂₂ n-3 PUFA on SREBP1 and ChREBP nuclear abundance [17]. Here we show that SCD1 mRNA parallels the induction of hepatic PPARγ2 mRNA and nuclear abundance in WD + O fed mice (Figures 9A & B). None of the diets containing EPA or DHA blocked the WD-mediated induction of nuclear PPARγ2. Nevertheless, DHA, but not EPA, suppressed SCD1 expression. DHA is a robust inhibitor of SREBP1 nuclear abundance [35]. Thus, DHA likely attenuatesMUFA synthesis by decreasing fatty acid synthase (FASN), ATP-citrate lyase (ACL) and SCD1 expression. Taken together, these results suggest that DHA-containing diets regulate hepatic 16:0, 18:1,n-7, and 18:1,n-9 content by controlling multiple genes involved in DNL and MUFA synthesis as well as the availability of substrates required for DNL. DHA suppression of DNL and MUFA synthesis, however, is not achieved by suppression of hepatic nuclear abundance of PPARγ2 (Figures 8 & 9).
Phospholipids and membrane remodeling

Feeding LDLR<sup>−/−</sup> mice the WD + O leads to a massive increase in total hepatic fat, composed predominantly of SFA and MUFA (Figure 10A). To examine the impact of this massive change in hepatic fat on membrane composition, we isolated hepatic phospholipids and examined the acyl chain composition (Figure 10B; Figure S1). When expressed as mole %, the sum of all SFAs in the phospholipid fraction was not affected by diet. In contrast, WD + O feeding elevated the sum of all MUFA in the phospholipid fraction by >100% (P < 0.05); MUFA was decreased significantly by the WD + E and WD + D diets, probably because of effects on DNL and MUFA synthesis described above. The WD + O diet significantly decreased n-3 PUFA in phospholipids, while the WD + E and WD + D diets significantly increased n-3 PUFA. The EPA and DHA-containing diets significantly decreased n-6 PUFA in phospholipids. Changes in phospholipid fatty acid composition are illustrated in Figure 11. Fatty acids most affected by diet were the MUFA (18:1, n-7 and n-9) and PUFA (20:4,n-6, 20:5,n-3 and 22:5,n-3). DHA in the phospholipid fraction was only elevated by DHA containing diets.

The metabolomic analysis identified 42 lysophospholipids. Lysophospholipids are generated during de novo phospholipid synthesis or during membrane remodeling. Of the 26 lysophospholipids with acyl chains in the sn-1 position, 4 were significantly affected by diet (Figure 12A). When compared to chow, 1-oleoylphosphoethanolamine was increased ~3-fold (p<0.05) in livers of mice fed the WD + O; the presence and absence of C<sub>20-22</sub> n-3 PUFA in WD had no effect on this change. One-linoleoylphosphoinositol was decreased by ~50% (p<0.05) by WD + E, only. Levels of 1-arachidonoylphosphocholine and –ethanolamine, but not –inositol were increased by the WD + O diet, while diets containing EPA or DHA decreased these lysophospholipids by >50% (p<0.05).

Of the 16 identified lysophospholipids with acyl chains in the sn-2 position, 4 were significantly affected by diet (Figure 12B). Hepatic 2-oleoylglycerol was increased ~3-fold (p<0.05) by WD + O regardless of the presence and absence of EPA and DHA, while hepatic levels of 2-linoleoylphosphoethanolamine were suppressed ≥50% (p<0.05) by WD + O. When compared to WD + O fed mice, hepatic levels of 2-arachidonoylphosphoglycerol-choline and –ethanolamine, but not -inositol, were suppressed by >60% (p<0.05). Hepatic levels of lysophospholipids containing DHA were not affected by diet.

This analysis revealed significant changes in lysophospholipids containing oleic, linolenic and arachidonic, but not DHA. This outcome suggests significant changes in
Diet effects on hepatic fat content. Panel A: Abundance of total hepatic SFA, MUFA, n-6 PUFA, and n-3 PUFA fatty acids analyzed from total lipid extracts using gas chromatography [8]. The sum of the fatty acids in each group (SFA, MUFA, n-3 and n-6 PUFA) is presented to illustrate the cumulative effects of diet on hepatic fat. Results are presented as total µmoles of fatty acid/g protein; mean ± SD in each fatty acid class; n=8/group. Panel B: Distribution of SFA, MUFA, n-6 PUFA, and n-3 PUFA in hepatic phospholipids. Hepatic phospholipids were fractionated by solid phase separation, saponified and methylated for GC analysis (see Fig, S1 for the quality of the separation of phospholipids from total lipids). Results are expressed as Fatty Acid Mole% in each fatty acid class, i.e., SFA, MUFA, N3 and N6-PUFA; mean ± SD, n=8/group.

doi: 10.1371/journal.pone.0083756.g010

Diet effects on hepatic phospholipid fatty acids. Individual fatty acids in the phospholipid fraction were quantified as described above and represented as Fatty Acid-Mole%, mean + SD, n=8/group; *, P ≤ 0.05 versus chow; #, P ≤ 0.05 versus WD + O.

doi: 10.1371/journal.pone.0083756.g011

Dietary effects on hepatic lysophospholipids. Panels A and B: Lysophospholipids were fractionated and quantified by the metabolomic analysis (LC/MS) as described in the Methods. Panel A: Lysophospholipids with acyl chains in the sn-1 position; Panel B: Lysophospholipids with acyl chains in the sn-2 position. The lysophospholipids are represented as Metabolite-Fold Change relative to chow; mean ± SD; n=8/group; *, P ≤ 0.05 versus chow; #, P ≤ 0.05 versus WD + O.

doi: 10.1371/journal.pone.0083756.g012

either de novo phospholipid synthesis or remodeling of membrane phospholipids. We examined the expression of enzymes involved in membrane remodeling; including four lysophosphatidylcholine acyl transferase subtypes (LPCAT1-4) and two phospholipase subtypes (iPLA2γ and PLA2γ6) (Figure 13). WD + O induced transcripts encoding all LPCAT subtypes (> 30%), while WD + D suppressed LPCAT1, 2, and 4 expression. The phospholipase, iPLA2γ, was unaffected by diet, while PLA2γ6 was induced (~2-fold, p<0.05) by the WD + O, regardless of the presence or absence of dietary C20-22 n-3 PUFA. Overall, this analysis showed that diet-induced changes in hepatic membrane lipid composition are influenced by substrate availability for membrane phosphoglycerolipid synthesis, as well as changes in the expression of enzymes involved in membrane remodeling.

Oxidized PUFA and lipid peroxidation

PUFA are sensitive to enzymatic and non-enzymatic mono-oxygenation (Figure 14). Enzymatic oxidation involving cyclooxygenases (COX), lipooxygenases (LOX) and CYP2 family members requires excision of the fatty acyl chain from membranes by phospholipases, while non-enzymatic lipid peroxidation likely results from increased hepatic oxidative stress affecting membrane PUFAs. The metabolomic analysis identified several oxidized PUFA generated from 18:2,n-6, 20:4,n-6 and 20:5,n-3 (Figure 15; Tables S2-S4). The prostaglandin (PG), 6-keto-PGF1α, was only detected in WD +
O fed mice. This oxidized fatty acid is generated from 20:4,n-6 by the action of cyclooxygenase and other enzymes; it is a degradation product of PGI2. 5-, 12- and 15-hydroxyeicosatetraenoic acid (HETE) are LOX products derived from 20:4,n-6. The WD + D diet was the most effective diet at suppressing WD-mediated accumulation of oxidized lipids derived from n-6 PUFA.

Two n-3 PUFA-derived oxidized lipids were detected; 18-HEPE and 17,18-DiHETE. 18-HEPE is derived from non-enzymatic or LOX-dependent mechanisms and is a precursor to resolvins [36]. 17,18-DiHETE is an epoxide hydrolase product of 17,18-epoxyeicosatetraenoic acid (17,18-EpETE); epoxide formation is catalyzed by CYP2 family members. The abundance n-3 PUFA-derived oxidized lipids paralleled changes in hepatic EPA levels (Figure 15).

To determine if changes in the hepatic abundance of these fatty acids are linked to enzyme expression, we quantified hepatic expression of COX1 & 2, LOX-5, -12, -15, several CYP2C family members as well as the soluble and microsomal epoxide hydrolases (EPHX1 & 2) (Figure 16). Expression of COX-1, COX-2, LOX-5 and LOX-15 were induced by the WD + O and suppressed the WD + D diet (Figure 16 A). Hepatic expression of several Cyp2C subtypes was suppressed by WD + O. In some cases, e.g., CYP2C29 and CYP2C37, WD + E containing diets reversed the effects of WD + O on these enzymes. Expression of EPHX1 & 2 subtypes was modestly induced by WD + E and WD + D diets (Figure 16B). Changes in the expression of the CYP2C and EPHX subtypes, however, did not correlate with changes in the 17,18-DiHETE metabolite.

In addition to the C20-derived oxidized PUFA, several 18,2n-6-derived oxidized fatty acids were detected, including 9,10-hydroxyoctadecenoic acid (9,10-DiHOME) and 9- and 13-hydroxyoctadecadienoic acids, i.e., isobar: 9-HODE and 13-HODE. While 9,10-DiHOME is formed in the CYP2C/EPHX pathway, 9-HODE and 13-HODE are derived through non-enzymatic mechanisms. When compared to chow-fed mice, the isobar representing 9-HODE and 13-HODE was suppressed in livers of all mice fed the WD, regardless of the presence or absence of C20-22 n-3 PUFA. 9,10-DiHome, in contrast, was suppressed >80% in the WD + O group only. For many of the oxidized fatty acids detected in the liver, the expression pattern of the enzymes involved, e.g., CYP2C and EPHX subtypes, does not parallel the hepatic abundance of the oxidized lipid suggesting the formation of these oxidized lipids is driven more by substrate availability than enzyme expression. Table S4 provides a correlation analysis between precursor and product indicating a strong association between polar lipid fatty acid availability and the hepatic abundance of the oxidized lipids.
Oxidative Stress and methylglyoxal metabolism

WD diets supplemented with EPA and/or DHA induced the formation of methionine sulfoxide in liver (Figure 7), a cellular marker of oxidative stress. We previously reported that LDLR-/- mice fed high fat-high cholesterol diets supplemented with menhaden oil had elevated urinary levels of F2- and F3-IsoP and neuroprostane-F4 (NP4) [17]. These iso- and neuroprostanes are derived from 20:4,n-6, 20:5,n-3 and 22:6,n-3, respectively. Herein, we quantified urinary F2- and F3-IsoP. When compared to chow-fed mice, mice fed WD + O had depressed urinary F3-IsoP, but no change in F2-IsoP (Figure 17 A). Inclusion of EPA or DHA in the WD significantly increased formation and excretion of both F2-IsoP and F3-IsoP. These results are in agreement with our previous study [17] and they indicate that dietary C20-22 n-3 PUFA induced isoprostane excretion, reflecting increased whole body lipid peroxidation.

The metabolomic analysis showed that LDLR-/- mice fed the WD + O had elevated hepatic α-tocopherol (vitamin E) and ascorbate (vitamin C) (~7-fold, p<0.05) when compared to chow-fed mice (Figure 17B). This increase was not due to increased dietary vitamin E or C. In fact, vitamin E content was independently quantified in both liver and the diets, and these analyses indicated that the chow diet and all western diets (WD) contained equivalent levels of vitamin E. When vitamin E was normalized to hepatic triglyceride content (hepatic vitamin E/mg triglyceride), hepatic vitamin E in the chow and WD + O groups was not different. In the WD + C20-22 n-3 PUFA groups, however, vitamin E was decreased by >60%. Thus, hepatic abundance of EPA and DHA affects hepatic vitamin E and C status. Since decreased hepatic vitamin E and C could promote oxidative stress, we quantified the nuclear abundance of nuclear factor-E2-related factor-2 (Nrf2), a major transcription factor involved in the anti-oxidant response (Figure 17C). Heterogeneous nuclear abundance of Nrf2 was increased ≥ 2-fold (p<0.05) in all mice consuming the WD, regardless of the presence or absence of C20-22 n-3 PUFA. As such, the WD induced an anti-oxidant response as reflected by increased hepatic nuclear content of Nrf2. Changes in nuclear Nrf2, however, do not parallel changes in hepatic vitamin C or E.

While hepatic GSH and GSSH levels were not significantly affected by diet, a glutathione metabolite was significantly affected, i.e., S-lactoylglutathione. S-lactoylglutathione is a detoxification product of methylglyoxal (Figure 18); and methylglyoxal is involved in the formation of advanced glycation end products (AGEP) and is implicated in fructose induced NASH [23,37]. Increased formation of S-lactoylglutathione is associated with more efficient detoxification of methylglyoxal and decreased AGEP formation.
While the hepatic level of S-lactoylglutathione was depressed by 83% (\(P < 0.05\)) in WD + O fed mice relative to controls, mice fed the WD + C \(20-22\) n-3 PUFA diets had ≥ 400% (\(P < 0.05\)) increase in S-lactoylglutathione (Figure 18B).

Factors governing hepatic S-lactoylglutathione are determined by substrate availability and enzyme activity (Figure 18A). Two enzymes, glyoxalase-1 & -2, are involved in the formation and degradation of S-lactoylglutathione. Expression of neither glyoxalase subtype was affected by diet (Figure 18C). Of the metabolites affecting methylglyoxal formation [23], hepatic glucose falls and both 3-phosphoglycerate and phosphoenolpyruvate were increased in mice fed the WD + C \(20-22\) n-3 PUFA diets (Figure 19). These outcomes suggest that dietary C \(20-22\) n-3 PUFA improves methylglyoxal detoxification by controlling substrate availability.

Discussion

We used a non-targeted global metabolomic approach to gain insight into mechanisms controlling C \(20-22\) n-3 PUFA attenuation of WD-induced NASH in LDLR\(^{-/-}\) mice. Both WD and dietary C \(20-22\) n-3 PUFA induced profound changes in metabolites linked to all major hepatic pathways (Figures 1-3; Table 1). In this report, we focused on changes in hepatic lipid, amino acid and vitamin metabolism. The accumulation of hepatic sphingomyelin, SFA, MUFA and n-6 PUFA, coupled with depletion of n-3 PUFA, likely plays a major role in NASH-associated pathologies, including hepatosteatosis, inflammation, oxidative stress and fibrosis. The capacity of dietary C \(20-22\) n-3 PUFA to lower hepatic sphingomyelin, SFA, MUF and n-6 PUFA as well as lower hepatic nuclear abundance of NFκB can explain many of the effects of n-3 PUFA on NASH-linked inflammation.

A major focus of our analysis was an assessment of metabolic factors that contribute to hepatic inflammation. In the WD-LDLR\(^{-/-}\) mouse model of NASH, hepatosteatosis is characterized by a massive accumulation of SFA and MUFA and a significant accumulation of n-6 PUFA, palmitoylsphingomyelin and cholesterol. Progression from hepatosteatosis to NASH requires mechanisms that promote inflammation and oxidative stress. Possible sources of inflammatory signals in this model include the high cholesterol diet which promotes high blood cholesterol levels [8]. This likely increases the formation of ox-LDL; and uptake of ox-LDL by Kupffer cells induces secretion of inflammatory cytokines [24]. A second source of inflammatory agents is endotoxin from the gut [25,26]. The increase in plasma endotoxin may be due to increased gut permeability or co-transport with chylomicron [26,29,30]. The WD + O diet induces plasma endotoxin ~15-fold (Figure 4). Whether this is due to loss of intestinal barrier function or increased endotoxin co-transport with chylomicron requires further study. Regardless of the cause, the cellular target of endotoxin is CD14, the plasma membrane receptor linking TLR4 to NFκB signaling. Once activated, NFκB subunits accumulate in nuclei and induce the transcription of multiple genes involved in inflammation, including MCP1 and TNFα, as well as the induction of multiple cell-surface markers (CD68, Clec4f, Clec10a, F4/80) on Kupffer cells and non-Kupffer leukocytes infiltrating the liver [8]. Inflammation promotes cell death, i.e., necroinflammation, cell debris accumulating from dying cells promotes inflammation by activating TLRs and other damage associated molecular pattern receptors associated with inflammasomes; these events exacerbate the inflammatory response [38].
Table 1. Summary of diet effects on Ldlr−/− mice.

| Parameter                               | WD + O versus Chow | O     | WD + D versus WD + O |
|-----------------------------------------|--------------------|-------|----------------------|
| **Plasma Markers:**                    |                    |       |                      |
| Plasma Endotoxin                        | Increase           | No Change |                      |
| Plasma AST                              | Increase           | Decrease |                      |
| NASH Markers                            |                    |       |                      |
| Steatosis                               | Increase           | Partial decrease |                |
| Inflammation (MCP1, CD68, TLR4)         | Increase           | Decrease |                      |
| Fibrosis (proCol1α1, TIMP1)             | Increase           | Decrease |                      |
| Trichrome staining                      | Increase           | Decrease |                      |
| **Oxidative Stress Markers:**          |                    |       |                      |
| α-Tocopherol                            | Increase           | Decrease |                      |
| Ascorbate                               | Increase           | Decrease |                      |
| GSH                                     | No Change          | No Change |                |
| GSSH                                    | No Change          | No Change |                |
| S-Lactoylglutathione                    | Increase           | Decrease |                      |
| Methionine Sulfoxide                    | No Change          | Increase |                      |
| HMOX1 Expression                       | Increase           | No Change |                |
| NOX2 Expression                         | Increase           | Decrease |                      |
| Urinary Isoprostanes                    | Decrease, F3-Isop  | Increase F2 & F3-Isop |          |
| **Fatty Acid Abundance:**              |                    |       |                      |
| SFA                                     | Increase           | No Change |                |
| MUFA                                    | Increase           | Decrease |                      |
| n-6 PUFA                                | Increase           | Decrease |                      |
| n-3 PUFA                                | Decrease           | Increase |                      |
| Sphingomyelin                           | Increase           | Decrease |                      |
| Phospholipids                           | Enriched in MUFA   | Decrease in MUFA | and N-6 PUFA |
| and N-6 PUFA                            | Depleted of N-3 PUFA | Increased in N-3 PUFA | |
| **Oxidized Fatty Acids:**              |                    |       |                      |
| n-6 PUFA derived                        | Increase           | Decrease |                      |
| n-3 PUFA derived                        | Decreased          | Increase |                      |
| **Transcription Factors:**             |                    |       |                      |
| NFκB-p50                                | Increase           | Decrease |                      |
| NFκB-p65                                | Increase           | No Change |                |
| SREBP1                                  | Increase           | Decrease |                      |
| PPARγ2                                  | Increase           | No Change |                |
| Nrf2                                    | Increase           | No Change |                |

doi: 10.1371/journal.pone.0083758.t001

WD + O induces several hepatic components involved in TLR signaling, including TLR2, TLR4, TLR9, CD14, but not MD2 or MyD88. WD + O also induced IL1β and the inflammasome marker [non-like receptor protein-3, NLRP3 (not shown)]. Dietary C20,22 n-3 PUFA attenuated expression of WD-induced TLRs and their components, plus IL1β and NLRP3 [8]. As plasma membrane associated proteins, CD14 and TLR4 function is governed by the composition of lipid rafts; membrane microdomains enriched in sphingomyelin, cholesterol and phospholipids enriched in SFA [39]. The WD + O increased hepatic sphingomyelin 6-fold; this likely increased membrane sphingomyelin and improved TLR4 activation of NFκB signaling in response to inflammatory signals like endotoxin. Increased sphingomyelin correlates with increased sphinganine abundance and increased expression of SPTLC1, 2 and SGMS1. These findings suggest WD increases hepatic sphingomyelin production.

Dietary EPA and DHA attenuates hepatic inflammation, at least in part, by suppressing de novo SFA, MUFA, and sphingomyelin production; this is achieved by suppressing substrate availability (citrate) and the expression of enzymes involved in these pathways (FASN, ACL, SCD1, SPTLC1, SGMS1) (Figures 6, 8, 9). Increased C20,22 n-3 PUFA consumption enriches membranes with n-3 PUFA and lowers n-6 PUFA content (Figure 11). These changes are known to disrupt lipid rafts [40]. Such changes in membrane composition are also associated with suppressed TLR4 and nuclear NFκB signaling in response to inflammatory signals, i.e., cytokines and plasma endotoxin.

The second major focus of our analysis was the effect of diet on hepatic and urinary oxidized lipids and markers of oxidative stress. Our previous studies indicated that high fat-high cholesterol diets induced changes in hepatic markers of oxidative stress [8,17], including Nrf2, GSTa1, HMOX1 and components of the NOX pathway (NOX1, NOX1, NOX1, NOX2, P22phox, P40phox, and P67phox). Oxidative stress has been a target for therapy in patients with NAFLD/NASH; and clinical studies have included both adults and children [41,42].

In the transition from the chow to the WD + O, hepatic triglyceride, n-6 PUFA, cholesterol, α-tocopherol, ascorbate, and Nrf2 nuclear content increase, while hepatic levels of n-3 PUFA, n-3 PUFA-derived oxidized lipids, and S-lactoylglutathione decrease. GSH and GSSH levels were not significantly affected by the WD + O (Figures 7, 15, 17, 18; Table 1). In the transition from the WD + O to the WD + EPA and/or DHA diets, urinary F2-Isop, F3-Isop and hepatic methionine sulfoxide, S-lactoylglutathione, and n-3 PUFA-derived oxidized lipids increase, while hepatic α-tocopherol and ascorbate are decreased. Hepatic GSH and GSSH were not significantly affected by the WD (Figure 7). Increased cellular C20,22 n-3 PUFA promoted lipid peroxidation and thus isoprostane formation (Figure 17) [17]. The decline in α-tocopherol and ascorbate is consistent with increased lipid peroxidation and isoprostane formation; α-tocopherol plays a role in protecting cells from lipoperoxide formation; while ascorbate, which is synthesized in mice, but not humans, plays a role in α-tocopherol recycling [43,44]. More important, however, is that the increased formation of n-3 and n-6 PUFA-derived isoprostanes, methionine sulfoxide and S-lactoylglutathione was associated with decreased gene expression markers of NASH [8]. This raises the question of whether n-3 derived isoprostanes/neuroprostanes and other n-3 PUFA derived oxidized fatty acids are hepatoprotective.
Our studies also reveal a strong correlation between hepatic content of EPA and DHA and the formation of 18-HEPE and 17,18-DiHETE. 18-HEPE is derived from EPA by a non-enzymatic process or a LOX-dependent mechanism. 18-HEPE is a precursor to resolvins, oxidized fatty acids with anti-inflammatory pro-resolving activity [36]. The epoxide hydroxylase product of 17,18-EpETE is 17,18-DiHETE; and 17,18-EpETE has recently shown to have cardioprotective effects [45]. While the metabolomic analysis did not identify 17,18-EpETE, we have recently detected and quantified 17,18-EpETE and 19,20-epoxy-docosapentaenoic acid (derived from DHA), and the corresponding epoxide hydrolase-derived diols. Using fractionated lipids (Figure S1; Figure SI) and LC/MS methods, we have identified both epoxy- and dihydroxy fatty acids derived from 20:4, n-6, 20:5, n-3 and 22:6, n-3. The epoxy fatty acids are found predominantly in the phospholipid fraction, while the diol fatty acids are found in the non-esterified fatty acid fraction. Cellular levels of these oxidized fatty acids parallel cellular levels of their precursors. Future studies will require determining whether these oxidized fatty acids regulate hepatic cell function.

Limitations and Conclusions

There are several limitations to our study. This research used the LDLR<sup>−/−</sup> mouse and the WD to induce NAFLD/NASH. While the relevance of this model to human NAFLD/NASH has not been established, LDLR<sup>−/−</sup> mice have provided considerable insight into processes linked to cardiovascular disease. NASH development in these mice is similar, but not identical to that seen in humans. For example, NOX4 induction is a major event in human NASH-associated fibrosis [46]. NOX4, however, is not induced by the WD in LDLR<sup>−/−</sup> mice. Instead, NOX2 was a major NOX subtype induced by the WD in LDLR<sup>−/−</sup> mice [8]. This may reflect species differences in how the NOX pathway generates superoxide and hydrogen peroxide, key factors in oxidative stress pathways. While studies investigating DHA supplementation in humans is sparse, we are aware of one study where DHA supplementation had benefit against NAFLD in children [47]. Several clinical trials are underway (6 clinical trials are listed on www.clinicaltrials.gov), but none are comparing the effects of EPA versus DHA on NASH progression.

A second limitation is that the metabolomic analysis is designed to detect small molecules. When these small molecules enter other compartments, such as membrane lipids like phosphoglycerolipids, they are not recovered by the extraction methods used for metabolomic analysis. A case in point is the analysis of epoxy and dihydroxy oxidized lipids described above. The identification of 17,18-DiHETE in our study, however, prompted further analysis to identify the precursor to this fatty acid and to search for similar oxidized fatty acids derived from ARA and DHA.

A third limitation is that the design of this metabolomic analysis does not allow us to establish cause and effect relationships. The goal of this study was to assess the breadth of effects of the WD, EPA and DHA on hepatic metabolism. In many cases we can relate changes in key pathways, e.g., fatty acid synthesis and inflammation (MCP1), to the control of specific transcription factors (SREBP1 and NFKB). Where there was no information, e.g., sphingomyelin, oxidized lipids or S-lactoylglutathione, we examined expression levels of enzymes involved in these pathways. This approach allowed us to determine whether changes in metabolites correlated with corresponding changes in gene expression. While this approach provides useful information, more studies are required to further define the mechanisms leading to changes in metabolites and expression of enzymes involved in these pathways.

Despite these limitations, the outcome of our metabolomic analysis established that the WD and dietary C<sub>20:2</sub> n-3 PUFA have broad effects on hepatic metabolism affecting all major metabolic pathways. Combined with our gene expression, immunoblot and histological analyses [8], the metabolomic analysis has provided an integrated view of the impact of diet on NASH progression and prevention. Dietary DHA>EPA attenuates NASH progression by regulating multiple processes, including membrane sphingomyelin and phosphoglycerolipid content, nuclear content of key transcription factors (NFKB, SREBP1, NRF2 and others), expression of genes involved in lipid metabolism, inflammation, oxidative stress, fibrosis, improved glucose metabolism, and detoxification of methylglyoxal. In addition, the EPA and DHA containing diets increased the formation of several oxidized lipids that may be hepatoprotective (epoxy- and/or di-hydroxy-fatty acid derivatives of EPA and DHA) (Table S4). Mechanisms for EPA and DHA control of membrane lipid content and the nuclear abundance of the transcripts mentioned above have been previously described[33]. The role EPA and DHA play in the control of cellular levels of antioxidants like α-tocopherol and ascorbate, and the role of n-3 PUFA-derived isoprostanes, epoxy- and dihydroxy-fatty acids play in NASH progression is novel. As such, more studies are required to establish how changes in these hepatic metabolites impact NASH progression. Methylglyoxal has been implicated in the progression of NASH [16]. Fructose, a major carbohydrate in the WD, promotes methylglyoxal formation and methylglyoxal is involved in the formation of AGEPs. Finding that addition of DHA to the WD improves methylglyoxal detoxification is equally novel and opens a new window of DHA regulates carbohydrate metabolism. Further definition of these pathways will help explain the sequence of events leading to NASH and its remission in response to dietary C<sub>20:2</sub> n-3 PUFA.

Supporting Information

File S1. Metabolic data provided by Metabolon, Inc. Results presented in the excel file are expressed as fold change in comparisons noted at the top of each column. Metabolites that were significantly changed by treatment are: in red if increased and in green if induced. The file also includes the statistical analysis (Welch’s two sample t-test). (XLSX)

Figure S1. Thin-layer chromatography of total hepatic and fractionated lipids. Total lipids were fractionated by solid phase chromatography using an aminopropyl cartridge. Total
and fractionated lipids were separated by thin layer chromatography as described in Methods. After separation, lipids were stained with iodine and photographed. Authentic chromatogram has three representative hepatic extracts for total lipids, NEFA, polar lipids and neutral lipids.

**Figure S2. Principle component analysis.** Separation of groups by principle component analysis (http://www.metaboanalyst.ca). Known metabolites in the 5 groups [chow (CH); WD + O (WDO); WDE (WD + E); WD + D (WDD); WD + E + D (WDC)] were included in the analysis. The explained variances are shown in brackets. The numbers in each bracket/group represents animal identification numbers.

**Table S1.** Primer pairs used for qRT-PCR.

**Table S2.** Volcano plot data comparing Chow versus WD + O fed mice. Volcano plots were prepared as described in Methods using software at (http://www.metaboanalyst.ca). This table represents the data used to construct Figure 3A.

**Table S3.** Volcano plot data comparing WD + O versus WD + D fed mice. Volcano plots were prepared as described in Methods using software at (http://www.metaboanalyst.ca). This table represents the data used to construct Figure 3B.

**Table S4.** Correlation of oxidized fatty acids with precursor fatty acids. Metabolites used to carry out a correlation analysis were quantified by the metabolomic analysis (Methods).

**Acknowledgements**

The authors thank Scott Leonard, Jaewoo Choi and Jeff Morre at the oxidative and nitrosative stress and the department of chemistry mass-spectrometry labs at OSU for the analysis of hepatic vitamin E and oxidized fatty acids.

**Author Contributions**

Conceived and designed the experiments: CMD DBJ. Performed the experiments: CMD KMB EK GM DBJ. Analyzed the data: CMD KMB EK GM DBJ. Contributed reagents/materials/analysis tools: MGT GB KMB EK. Wrote the manuscript: CMD DBJ.

**References**

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142: 1592-1609.

2. McCullough AJ (2008) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 42 Suppl 1: S17-S29. PubMed: 16540762.

3. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274-285. doi:10.1111/j.1365-2036.2011.04724.x. PubMed: 21623852.

4. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK et al. (2011) Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141: 1249-1253. doi:10.1053/j.gastro.2011.06.061. PubMed: 21726509.

5. Day CP, James OF (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114: 842-845. doi:10.1016/S0016-5085(98)70599-2. PubMed: 9547102.

6. Lam BP, Younossi ZM (2009) Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol 8 Suppl 1: S51-S59. PubMed: 19381125.

7. Musso G, Gambino R, Cassader M (2010) Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 11: 430-445. PubMed: 19845871.

8. Depner CM, Philbrick KA, Jump DB (2013) Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr/-/- mouse model of western diet-induced nonalcoholic steatohepatitis. J Nutr 143: 315-323. doi: 10.3945/jn.112.171322. PubMed: 23303872.

9. de Wit NJ, Afman LA, Mensink M, Müller M (2012) Phenotyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol 57: 1370-1373. doi:10.1016/j.jhep.2012.07.003. PubMed: 22796155.

10. Martel C, Espositi DD, Bouchet A, Brenner C, Lemoine A (2012) Non-alcoholic steatohepatitis: new insights from OMICS studies. Curr Pharm Biotechnol 13: 726-735. doi:10.2174/138920112799857558. PubMed: 22122481.

11. Kalhan SC, Guo L, Edmister J, Dasarathy S, McCullough AJ et al. (2011) Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 60: 404-413. doi:10.1016/j.metabol.2010.03.006. PubMed: 20423748.

12. Barr J, Vázquez-Chantada M, Alonso C, Pérez-Cormenzana M, Mayo R et al. (2010) Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res 9: 4501-4512. doi:10.1021/pr1002593. PubMed: 20864516.

13. Kalish BT, Le HD, Gura KM, Bistrian BR, Puder M (2013) A metabolomic analysis of two intravenous lipid emulsions in a murine model. PLOS ONE 8: e59653. doi:10.1371/journal.pone.0059653. PubMed: 23565157.

14. Puri P, Baillie RA, West MM, Mirshahi F, Choudhury J et al. (2007) A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46: 1081-1090. doi:10.1002/hep.21763. PubMed: 17654743.

15. Garcia-Heredia A, Kansicki E, Mohney RP, Rull A, Triguero I et al. (2013) Paraoxonase-1 Deficiency Is Associated with Severe Liver Steatosis in Mice Fed a High-fat High-cholesterol Diet: A Metabolomic. Approach - J Proteome Res (In press).

16. Wei Y, Wang D, Moran G, Estrada A, Pagliassotti MJ (2013) Fructose-induced stress signaling in the liver involves methylglyoxal. Nutr (Lond) 10: 32-38. doi:10.1186/1743-7075-10-32.

17. Depner CM, Torres-Gonzalez M, Tripathy S, Milne G, Jump DB (2012) Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr/-/- mice. J Nutr 142: 1495-1503. doi:10.3945/jn.112.158865. PubMed: 22739374.

18. Saraswathi V, Gao L, Morrow JD, Chait A, Niswender KD et al. (2007) Fish oil increases cholesterol storage in white adipose tissue with concomitant decreases in inflammation, hepatic steatosis, and atherosclerosis in mice. J Nutr 137: 1776-1782. PubMed: 17585030.

19. Milne GL, Yin H, Morrow JD (2008) Human biochemistry of the isoprostane pathway. J Biol Chem 283: 15533-15537. doi:10.1074/jbc.R700047200. PubMed: 18285331.

20. Tripathy S, Torres-Gonzalez M, Jump DB (2010) Elevated hepatic fatty acid elongase-5 activity corrects dietary fat-induced hyperglycemia in LDLR-/- Mice.
Metabolic endotoxemia initiates obesity and insulin resistance. (Lond) 7: 15. doi:10.1186/1476-9255-7-15. PubMed: 20353583.

Dobrzyn A, Dobrzyn P, Lee SH, Miyazaki M, Cohen P et al. (2005) Stearoyl-CoA desaturase-1 deficiency reduces ceramide synthesis by downregulating serine palmitoyltransferase and increasing beta-oxidation in skeletal muscle. Am J Physiol Endocrinol Metab 288: E599-E607. PubMed: 15562249.

Botolin D, Wang Y, Christian B, Jump DB (2006) Docosahexaenoic acid (22:6,ω-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk- and 26S proteasome-dependent pathways. J Lipid Res 47: 181-192. PubMed: 16253479.

Weylandt KH, Chiu CY, Gomolka B, Waechter SF, Wiedemann B (2012) Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins Other Lipid Mediat 97: 73-82. doi:10.1016/j.prostaglandins.2012.01.005. PubMed: 22326554.

Wei Y, Wang D, Moran G, Estrada A, Pagliassotti MJ (2013) Fructose-induced stress signaling in the liver involves methylglyoxal. Nutr Metab (Lond) 10: 32. doi:10.1186/1743-7075-10-32. PubMed: 23666306.

Marra F, Gastaldelli A, Baroni GS, Tell G, Tiribelli C (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Hepatology 52: 642-654. doi:10.1016/j.hep.2012.03.035. PubMed: 22634126.

Simons K, Ikonen E (1997) Functional rafts in cell membranes. Nature 387: 569-572. doi:10.1038/42408. PubMed: 9177342.

Wassali SR, Stillwell W (2006) Docosahexaenoic acid domains: the ultimate non-raft membrane domain. Chem Phys Lipids 153: 57-63. doi:10.1016/j.chemphys.2008.02.010. PubMed: 18342224.

Lavine JE, Schwimmer JB, Van Natta ML, Molloston JP, Murray KF et al. (2011) Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305: 1659-1668. doi:10.1001/jama.2011.520. PubMed: 21521847.

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM et al. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic fatty liver disease in children: double-blind randomised controlled trial. Arch Dis Child 96: 350-353. doi:10.1136/adc.2010.192401. PubMed: 21233083.

Ikeda R, Ishii K, Hoshikawa Y, Azumi J, Arakaki Y et al. (2011) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1675-1685. doi:10.1056/NEJMoat0907929. PubMed: 20427778.

Thurman GR (1993) The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 300: 535-543. doi:10.1016/0003-9861(93)90046-H. PubMed: 8434935.

Wahby MG (2007) Vitamin E regulatory mechanisms. Annu Rev Nutr 27: 347-362. doi:10.1146/annurev.nutr.27.061406.093819. PubMed: 17439363.

Arnold C, Markovic M, Blossey K, Wallukat G, Fischer R et al. (2010) Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of omega-3 fatty acids. J Biol Chem 285: 32720-32733. doi:10.1074/jbc.M110.118406. PubMed: 20732876.

Ikeda R, Ikari K, Hoshikawa Y, Azumi J, Arakaki Y et al. (2011) Reactive oxygen species and NADPH oxidase 4 induced by transforming growth factor beta1 are the therapeutic targets of polyethylenepolyglycolylcholine in the suppression of human hepatic stellate cell activation. Inflamm Res 60: 597-604. doi:10.1007/s00011-011-0309-6. PubMed: 21318733.

Nobili V, Bedogni G, Alisi A, Pietrobelli A, Risé P et al. (2011) Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 96: 350-353. doi:10.1136/adc.2010.192401. PubMed: 21233083.